Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 13Carcinoma, Renal Cell 6Tuberous Sclerosis 5Neoplasm Metastasis 5Hodgkin Disease 5Glioblastoma 5Colorectal Neoplasms 5Central Nervous System Neoplasms 5Waldenstrom Macroglobulinemia 4Stomach Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Lymphoma, Mantle-Cell 4Head and Neck Neoplasms 4Gliosarcoma 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sezary Syndrome 3Recurrence 3Prostatic Neoplasms 3Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Kidney Neoplasms 3

Interventions

Cyclophosphamide 3Imatinib Mesylate 2temsirolimus 1tazemetostat 1sapanisertib 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1lentiviral minigene vaccine of COVID-19 coronavirus 1aldesleukin 1Zoledronic Acid 1Sunitinib 1Ramucirumab 1Nivolumab 1Methotrexate 1Leukapheresis 1Interleukin-2 1Injections 1Immunotherapy, Adoptive 1Ifosfamide 1HhAntag691 1Gemcitabine 1Everolimus 1Epirubicin 1Doxorubicin 1Docetaxel 1Decitabine 1Dacarbazine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma, Synovial × Everolimus × Clear all
NCT01281865 2014-10-08

Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
14 enrolled 7 charts
Sarcoma

Sarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡